Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

M-Vax: A Feasibility and Bio-Equivalence Study Using a DNP-Modified Autologous Melanoma Tumor Cell Vaccine as Therapy in Patients With Stage III or IV Melanoma

NCT00257465 is registered in ClinicalTrials.gov with AVAX Technologies as lead sponsor.

NCT NCT00257465
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00257465 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
M-Vax: A Feasibility and Bio-Equivalence Study Using a DNP-Modified Autologous Melanoma Tumor Cell Vaccine as Therapy in Patients With Stage III or IV Melanoma
Lead sponsor
AVAX Technologies
Phase
Phase 1/2
Overall status
Completed
Start date
June 30, 2005
Completion date
June 30, 2008
Enrollment
82 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma